[{"id":"c87b3fa1-5757-47ff-91bc-735d94b38949","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805943","created_at":"2023-04-10T14:03:09.231Z","updated_at":"2024-07-02T16:35:51.034Z","phase":"Phase 1/2","brief_title":"Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05805943","lead_sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e amouravfop alfa (IMM0306)"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 03/02/2020","start_date":" 03/02/2020","primary_txt":" Primary completion: 05/25/2025","primary_completion_date":" 05/25/2025","study_txt":" Completion: 05/25/2025","study_completion_date":" 05/25/2025","last_update_posted":"2023-04-10"}]